Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis

Armstrong, Amy E.; Dargart, Jamie L.; Reichek, Jennifer; Walterhouse, David; Matossian, Debora; Cohn, Richard A.; Gosiengfiao, Yasmin

doi:10.1002/pbc.24869

Cited by 10 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reports have described patients with high-risk neuroblastoma developing renal failure,5 but no reports are available on HDCT with auto-PBSCT in a pediatric patient with neuroblastoma under ESRD. Armstrong et al6 prescribed consolidation treatment with irinotecan and temozolomide for their patient with high-risk neuroblastoma requiring maintenance HD. The patient safely underwent consolidation therapy, but the disease progressed after several months.…”

Section: Discussionmentioning

confidence: 99%

Successful High-dose Chemotherapy in Combination With Autologous Peripheral Blood Stem Cell Transplantation in an Anuric Child With Neuroblastoma

Inoguchi¹,

Hamada²,

Wataru³

et al. 2021

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

No reports describe high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplantation (auto-PBSCT) in pediatric patients with neuroblastoma and end-stage renal disease. Here, we report the case of a patient with high-risk neuroblastoma who developed anuria during treatment. HDCT with auto-PBSCT under hemodialysis, with strict attention to the ultrafiltration volume and dose modification of alkylating agents, was performed. Although the first auto-PBSCT led to engraftment failure, the second auto-PBSCT resulted in successful myeloid engraftment 8 months after anuria. This case demonstrated that HDCT with auto-PBSCT can be safely performed in children with renal failure under hemodialysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful High-dose Chemotherapy in Combination With Autologous Peripheral Blood Stem Cell Transplantation in an Anuric Child With Neuroblastoma

Inoguchi¹,

Hamada²,

Wataru³

et al. 2021

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

“…A large number of studies have confirmed that patients with chronic renal failure (CRF) have a higher incidence of malignant tumors and mortality[ 4 , 5 ]. When the estimated glomerular filtration rate (GFR) drops to 10 mL/min/1.73 m 2 , the mortality rate of cancer patients increases by 22%[ 6 , 7 ]. Therefore, the reduction in GFR will not only lead to serious renal complications, but also limit the treatment of tumors, thereby promoting tumor progression.…”

Section: Introductionmentioning

confidence: 99%

Individualized treatment of breast cancer with chronic renal failure: A case report and review of literature

Cai¹,

Zheng²,

Lin³

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Studies have shown that patients with chronic renal failure (CRF) are more likely to suffer from breast cancer and other malignant tumors. To our knowledge, CRF can reduce drug excretion, thereby increase drug exposure and lead to increased toxicity, which will limit drug treatment and lead to tumor progression. Currently, there are few successful reports on the combination of docetaxel, trastuzumab, and pertuzumab (THP) as a neoadjuvant treatment regimen for breast cancer patients with CRF. CASE SUMMARY We report a breast cancer (cT2N2M0, Her-2+/HR-) patient with CRF. It was a clinical stage IIIA tumor on the left breast. The patient had suffered from uremia for 2 years, and her heart function was normal. Based on the pathological type, molecular type, and clinical stage of breast cancer, and the patient’s renal function, the clinician analyzed the pharmacological and pharmacokinetic characteristics of the antitumor drugs after consulting the relevant literature, and prescribed the neoadjuvant regimen of THP (docetaxel 80 mg/m², trastuzumab 8 mg/kg for the first dose, and 6 mg/kg for the maintenance dose with pertuzumab 840 mg for the first dose and 420 mg for the maintenance dose), once every 3 wk, for a total of 6 courses. The neoadjuvant treatment had a good effect, and the patient then underwent surgery which was uneventful. CONCLUSION CRF is not a contraindication for systemic treatment and surgery of breast cancer. The THP regimen without dose adjustment may be a safe and effective neoadjuvant treatment for HER-2 positive breast cancer patients with CRF.

show abstract

“…These patients generally have a high mortality. The mortality rate of a cancer patient increases by 22 % when the estimated glomerular filtration rate (GFR) decreases to 10 mL/min/1.73 m 2 [ 1 , 2 ]. This finding can be attributed to the fact that GFR reduction not only induces severe kidney complications but also restricts tumor treatment, thereby promoting tumor progression.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report

Liu

Zhang

et al. 2015

BMC Cancer

View full text Add to dashboard Cite

BackgroundStandardized chemotherapy used in cancer patients with severe kidney insufficiency is ineffective. Although there are some pharmacokinetic studies on cyclophosphamide in kidney insufficiency patients, to the best of our knowledge, the pharmacokinetics and safety of combination of cyclophosphamide and docetaxel as postoperative chemotherapy in a patient with early stage breast cancer undergoing hemodialysis is unclear thus far.Case PresentationThe patient received regular TC regimen (cyclophosphamide 600 mg/m2, docetaxel 75 mg/m2). She underwent hemodialysis 48 h after chemotherapy. Blood samples at multiple time-points were collected for determination of plasma levels of cyclophosphamide and docetaxel. Pharmacokinetic analyses indicated that compared with the reference data, the in vivo half-life (66.96 h) and drug exposure (150 %) of cyclophosphamide significantly increased; however, pharmacokinetic parameters of docetaxel was unaffected. Patient developed grade I thrombocytopenia and grade III leukopenia without any other severe adverse reactions. In total, four cycles of treatment were completed. After the chemotherapy, the patient received tamoxifen as endocrine therapy for one and a half years. No recurrence was reported.ConclusionThese results suggest that the standard TC regimen is mostly safe and could be used as postoperative adjuvant chemotherapy for hemodialysis patients with early stage breast cancer.

show abstract

Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis

Cited by 10 publications

References 15 publications

Successful High-dose Chemotherapy in Combination With Autologous Peripheral Blood Stem Cell Transplantation in an Anuric Child With Neuroblastoma

Successful High-dose Chemotherapy in Combination With Autologous Peripheral Blood Stem Cell Transplantation in an Anuric Child With Neuroblastoma

Individualized treatment of breast cancer with chronic renal failure: A case report and review of literature

Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report

Contact Info

Product

Resources

About